发明公开
EP2021016A2 CXCL13 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES
有权
CXCL-13拮抗剂和TNF-α拮抗剂联合使用治疗
- 专利标题： CXCL13 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES
- 专利标题（中）： CXCL-13拮抗剂和TNF-α拮抗剂联合使用治疗
-
申请号： EP07761002.0申请日： 2007-04-20
-
公开(公告)号： EP2021016A2公开(公告)日： 2009-02-11
- 发明人: BUGELSKI, Peter , DAS, Anuk , GRISWOLD, Donald E. , LIANG, Bailin , LI, Li , SARISKY, Robert A. , SHANG, Xiaozhou
- 申请人： CENTOCOR, INC.
- 申请人地址： 200 Great Valley Parkway, Mailcode RA-1-5 Malvern, PA 19355 US
- 专利权人： CENTOCOR, INC.
- 当前专利权人： CENTOCOR, INC.
- 当前专利权人地址： 200 Great Valley Parkway, Mailcode RA-1-5 Malvern, PA 19355 US
- 代理机构： Marshall, Cameron John
- 优先权： US794018P 20060421; US909128P 20070330
- 国际公布： WO2007124414 20071101
- 主分类号： A61K38/28
- IPC分类号： A61K38/28
摘要：
Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNFα antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic lupus erythematosus.
公开/授权文献
信息查询
IPC分类:
